Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashish Shah

Foot and Ankle Surgery Birmingham, AL Medical Doctor

NPI 1972832467 CMS profile 361865

1201 11Th Ave S, Suite 200, Birmingham, AL 35205

Open in the dashboard

General payments

$28,395

148 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashish Shah of Birmingham, AL is reported in the CMS Open Payments database as having received $28,395 across 148 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,337 23
2024 General $4,575 20
2023 General $6,426 29
2022 General $6,585 29
2021 General $5,559 26
2020 General $104 3
2019 General $1,808 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashish Shah
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Ashish Shah were reported at $3,337. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Ashish Shah Foot and Ankle Surgery median Middle half National median
2019 $1,808 $1,327 $279–$5,421 $163
2020 $104 $795 $121–$3,473 $114
2021 $5,559 $1,289 $201–$4,963 $132
2022 $6,585 $1,539 $270–$6,067 $149
2023 $6,426 $1,117 $257–$5,264 $160
2024 $4,575 $1,064 $235–$4,944 $164
2025 $3,337 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Crossroads Extremity Systems, LLC $4,846 9 payments
  2. AbbVie, Inc. $4,812 6 payments
  3. DePuy Synthes Sales Inc. $3,136 20 payments
  4. Medical Device Business Services, Inc. $3,000 2 payments
  5. International Life Sciences $2,916 2 payments
  6. Stryker Corporation $1,977 23 payments
  7. Bioventus LLC $1,495 18 payments
  8. Smith+Nephew, Inc. $1,120 14 payments
  9. Biosense Webster, Inc. $761 1 payment
  10. MedShape, Inc. $722 3 payments
  11. Other $3,609 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,558 112 payments
  2. Consulting Fee $7,250 3 payments
  3. Travel and Lodging $5,401 11 payments
  4. Royalty or License $3,386 21 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,800 1 payment
Products named General payments · program years 2019–2025
  1. VENCLEXTA $4,812 6 payments
  2. Medical Implant $4,701 6 payments
  3. Durolane $1,330 6 payments
  4. MOTOBAND $1,069 8 payments
  5. Thermocool SF $761 1 payment
  6. AUGMENT INJECTABLE $661 5 payments
  7. Arsenal Sinus Support Plate $595 2 payments
  8. DynaNail Mini $522 1 payment
  9. ANCHORAGE $330 3 payments
  10. SiFix $305 3 payments
  11. Other $6,822 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

52

Median for Orthopedic Surgery: 203

Drug cost

$351

Median for Orthopedic Surgery: $1,433

Branded share of claims

28.8%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 24 $220
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 15 $86
Meloxicam Generic 13 $45

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$64,310

Of which drugs: $338

Medicare patients

177

Average age 67

Services billed

505

113 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 31%
Diabetes 28%
Ischemic heart disease 27%
Chronic kidney disease 26%
COPD 23%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 11 61 $338

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

148 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record